X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1687) 1687
humans (1501) 1501
niacinamide - analogs & derivatives (981) 981
phenylurea compounds (977) 977
animals (842) 842
male (751) 751
benzenesulfonates - chemistry (749) 749
benzenesulfonates - therapeutic use (676) 676
benzenesulfonates - pharmacology (626) 626
female (615) 615
pyridines - therapeutic use (564) 564
oncology (546) 546
sorafenib (531) 531
benzenesulfonates (478) 478
cancer (441) 441
antineoplastic agents - therapeutic use (439) 439
middle aged (418) 418
aged (368) 368
benzenesulfonates - administration & dosage (330) 330
analysis (323) 323
adult (318) 318
environmental sciences (311) 311
mice (302) 302
treatment outcome (297) 297
benzenesulfonates - adverse effects (282) 282
pharmacology & pharmacy (263) 263
rats (254) 254
pyridines - administration & dosage (252) 252
pyridines - adverse effects (247) 247
pyridines - pharmacology (247) 247
kinetics (244) 244
hydrogen-ion concentration (234) 234
carcinoma, hepatocellular - drug therapy (233) 233
research (233) 233
liver neoplasms - drug therapy (232) 232
biochemistry & molecular biology (230) 230
kidney neoplasms - drug therapy (230) 230
carcinoma, renal cell - drug therapy (228) 228
cell line, tumor (228) 228
care and treatment (224) 224
time factors (204) 204
protein kinase inhibitors - therapeutic use (187) 187
chemistry, analytical (186) 186
benzenesulfonates - metabolism (183) 183
azo compounds - chemistry (182) 182
antineoplastic agents (173) 173
adsorption (172) 172
article (166) 166
antimitotic agents (165) 165
antineoplastic agents - adverse effects (165) 165
antineoplastic agents - pharmacology (160) 160
expression (159) 159
sunitinib (156) 156
angiogenesis (154) 154
benzenesulfonates - analysis (153) 153
bevacizumab (151) 151
dose-response relationship, drug (151) 151
degradation (147) 147
aged, 80 and over (146) 146
liver cancer (144) 144
apoptosis (142) 142
engineering, environmental (141) 141
oxidation-reduction (140) 140
hepatocellular carcinoma (139) 139
endothelial growth-factor (137) 137
indoles - therapeutic use (135) 135
drug therapy (133) 133
pyrroles - therapeutic use (132) 132
dyes (131) 131
medicine & public health (131) 131
chemotherapy (130) 130
benzenesulfonates - toxicity (129) 129
gastroenterology & hepatology (129) 129
antineoplastic combined chemotherapy protocols - therapeutic use (128) 128
cell proliferation - drug effects (127) 127
biochemical research methods (125) 125
microbiology (123) 123
survival (122) 122
water (122) 122
proteins (121) 121
temperature (118) 118
antitumor-activity (117) 117
coloring agents - chemistry (117) 117
biotechnology & applied microbiology (116) 116
metastasis (116) 116
kidney neoplasms - pathology (115) 115
prognosis (115) 115
health aspects (114) 114
apoptosis - drug effects (113) 113
therapy (113) 113
catalysis (112) 112
renal cell carcinoma (111) 111
tumors (110) 110
disease models, animal (108) 108
liver neoplasms - pathology (108) 108
hepatoma (107) 107
carcinoma, hepatocellular - pathology (106) 106
carcinoma (105) 105
disease-free survival (103) 103
sensitivity and specificity (102) 102
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3080) 3080
Chinese (43) 43
German (22) 22
Russian (15) 15
Japanese (7) 7
Spanish (5) 5
French (4) 4
Czech (2) 2
Hungarian (2) 2
Italian (2) 2
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 08/2010, Volume 18, Issue 15, pp. 5738 - 5748
Here, we present a structural comparison of the important and similar interactions necessary for Gleevec®, Nexavar®, and BIRB-796 to bind to their respective... 
Allosteric structure based drug design kinase type II | CHEMISTRY, MEDICINAL | PROTEIN | C-ABL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | SORAFENIB | CANCER | P38 MAP KINASE | HEPATOCELLULAR-CARCINOMA | MELANOMA | BRAF MUTATIONS | IMATINIB | B-RAF | Niacinamide - analogs & derivatives | Mitogen-Activated Protein Kinase 14 - antagonists & inhibitors | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Pyridines - chemistry | Allosteric Regulation | Antineoplastic Agents - chemical synthesis | Crystallography, X-Ray | Phenylurea Compounds | Piperazines - chemistry | Pyrimidines - chemistry | Benzenesulfonates - pharmacology | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Mitogen-Activated Protein Kinase 14 - metabolism | Computer Simulation | Drug Design | Antineoplastic Agents - pharmacology | Oligopeptides - chemistry | Proto-Oncogene Proteins B-raf - metabolism | Pyrazoles - pharmacology | Naphthalenes - chemistry | Amino Acid Sequence | Protein Kinase Inhibitors - chemical synthesis | Catalytic Domain | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Imatinib Mesylate | Piperazines - pharmacology | Naphthalenes - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Benzenesulfonates - chemistry | Hydrogen Bonding | Proto-Oncogene Proteins c-abl - metabolism | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Benzamides | Adenosine Triphosphate - chemistry | Antimitotic agents | Chemical properties | Antineoplastic agents | Pharmacy | Analysis | Index Medicus
Journal Article
Journal Article
Stroke, ISSN 0039-2499, 06/2008, Volume 39, Issue 6, pp. 1751 - 1758
Journal Article
Journal Article
Journal Article
BJU International, ISSN 1464-4096, 06/2009, Volume 103, Issue 12, pp. 1636 - 1640
OBJECTIVE To determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria... 
castration-resistant prostate cancer | sorafenib | Raf-kinase inhibitor | angiogenesis | castration‐resistant prostate cancer | Raf‐kinase inhibitor | MITOXANTRONE | SAFETY | RAF KINASE | 2ND-LINE CHEMOTHERAPY | DOCETAXEL | PREDNISONE | PHARMACOKINETICS | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | REFRACTORY SOLID TUMORS | INHIBITOR | Niacinamide - analogs & derivatives | Bone Neoplasms - mortality | raf Kinases - antagonists & inhibitors | Humans | Middle Aged | Bone Neoplasms - secondary | Soft Tissue Neoplasms - drug therapy | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Neoplasm Metastasis | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Gonadotropin-Releasing Hormone - therapeutic use | Bone Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Pyridines - therapeutic use | Soft Tissue Neoplasms - mortality | Prostatic Neoplasms - surgery | Soft Tissue Neoplasms - secondary | Treatment Outcome | Prostatic Neoplasms - mortality | Orchiectomy | Disease-Free Survival | Aged | Antigens | Usage | Oncology, Experimental | Clinical trials | Metastasis | Research | Antineoplastic agents | Antimitotic agents | Chemotherapy | Analysis | Product development | Prostate cancer | Cancer | Index Medicus | castration resistant prostate cancer
Journal Article
Journal Article
BJU International, ISSN 1464-4096, 10/2011, Volume 108, Issue 8b, pp. E250 - E257
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2011, Volume 72, Issue 2, pp. 294 - 305
Journal Article